Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Hansa Biopharma AB
24HCurrent price
2.90 EUR
-0.008 EUR (-0.28%)
Last closed
33.58 SEK
Company
www.hansabiopharma.com
ISIN
SE0002148817
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
2 197 454 726 SEK
Yield for 12 month
-3.38 %
1Y
3Y
5Y
10Y
15Y
24H
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. Address: ScheelevAegen 22, Lund, Sweden, 223 63
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1 134.22 SEKP/E ratio
–Dividend Yield
–Current Year
+133 746 111 SEK
Last Year
+154 124 108 SEK
Current Quarter
+48 537 743 SEK
Last Quarter
+34 244 930 SEK
Current Year
+70 766 933 SEK
Last Year
+115 746 931 SEK
Current Quarter
+37 187 277 SEK
Last Quarter
-6 177 936 SEK
Key Figures 24H
1 year
3 years
5 years
10 years
EBITDA
-621 688 202 SEK
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-37.08 %
PEG Ratio
–
Return On Equity TTM
-4 176.67 %
Wall Street Target Price
1 134.22 SEK
Revenue TTM
188 898 653 SEK
Book Value
-4.71 SEK
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
113.10 %
Dividend Yield
–
Gross Profit TTM
100 935 455 SEK
Earnings per share
-11.00 SEK
Diluted Eps TTM
-11.00 SEK
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 24H
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History 24H
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1015:964
Payout Ratio
–
Last Split Date
16.03.2015
Dividend Date
–
Stock Valuation 24H
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
14.19
Price Sales TTM
11.63
Enterprise Value EBITDA
-3.89
Price Book MRQ
8.05
Financials 24H
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 24H
For 52 weeks
25.83 SEK
57.15 SEK
50 Day MA
33.49 SEK
Shares Short Prior Month
–
200 Day MA
39.07 SEK
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart